EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers

Mathias Lemarchand, Kiefer Thouin, Thiéry De Serres-Bérard iD, Sabrina Bellenfant, Sébastien Cadau, François Berthod iD

Biotechnology and Bioengineering · 2023

DOI: 10.1002/bit.28359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2023. Verfasst von Mathias Lemarchand und 5 weiteren Autor:innen. Beteiligte Einrichtung: LOEX, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada. Hauptthemen laut MEDLINE: Diabetic Foot, Diabetes Mellitus. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic foot ulcers are a major complication of diabetes that occurs following minor trauma. Diabetes‐induced hyperglycemia is a leading factor inducing ulcer formation and manifests notably through the accumulation of advanced glycation end‐products (AGEs) such as N‐carboxymethyl‐lysin. AGEs have a negative impact on angiogenesis, innervation, and reepithelialization causing minor wounds to evolve into chronic ulcers which increases the risks of lower limb amputation. However, the impact of AGEs on wound healing is difficult to model (both in vitro on cells, and in vivo in animals) because it involves a long‐term toxic effect. We have developed a tissue‐engineered wound healing model made of human keratinocytes, fibroblasts, and endothelial cells cultured in a collagen sponge biomaterial. To mimic the deleterious effects induced by glycation on skin wound healing, the model was treated with 300 µM of glyoxal for 15 days to promote AGEs formation. Glyoxal treatment induced carboxymethyl‐lysin accumulation and delayed wound closure in the skin mimicking diabetic ulcers. Moreover, this effect was reversed by the addition of aminoguanidine, an inhibitor of AGEs formation. This in vitro diabetic wound healing model could be a great tool for the screening of new molecules to improve the treatment of diabetic ulcers by preventing glycation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic FootDiabetes MellitusAnimalsHumansMaillard ReactionEndothelial CellsWound HealingGlycation End Products, AdvancedGlyoxal

Stichwörter der Autor:innen

AGEdiabetesglycationkeratinocytestissue engineeringwound healing

Substanzen

Glycation End Products, AdvancedGlyoxal

Autor:innen und Institutionen

  • LOEX, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada.
  • Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, Canada.

ORCID-Profile: Thiéry De Serres-Bérard, François Berthod

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Lemarchand, M., Thouin, K., De Serres-Bérard, T., Bellenfant, S., Cadau, S., & Berthod, F. (2023). In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28359

Vancouver

Lemarchand M, Thouin K, De Serres-Bérard T, Bellenfant S, Cadau S, Berthod F. In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28359

BibTeX
@article{Lemarchand2023,
  author = {Lemarchand, Mathias and Thouin, Kiefer and De Serres-Bérard, Thiéry and Bellenfant, Sabrina and Cadau, Sébastien and Berthod, François},
  title = {In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  doi = {10.1002/bit.28359}
}
Kostenlos starten →